Arctic Bioscience Future Growth
Future criteria checks 2/6
Arctic Bioscience's earnings are forecast to decline at 6% per annum while its annual revenue is expected to grow at 40% per year. EPS is expected to decline by 6.1% per annum. Return on equity is forecast to be -17.6% in 3 years.
Key information
-6.0%
Earnings growth rate
-6.1%
EPS growth rate
Biotechs earnings growth | -10.2% |
Revenue growth rate | 40.0% |
Future return on equity | -17.6% |
Analyst coverage | Low |
Last updated | 31 Jan 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 79 | -51 | -50 | -42 | 1 |
12/31/2024 | 57 | -31 | -31 | -23 | 1 |
12/31/2023 | 34 | -46 | -86 | -40 | N/A |
9/30/2023 | 36 | -43 | -85 | -37 | N/A |
6/30/2023 | 39 | -40 | -85 | -34 | N/A |
3/31/2023 | 37 | -37 | -84 | -30 | N/A |
12/31/2022 | 34 | -34 | -84 | -25 | N/A |
9/30/2022 | 29 | -35 | -80 | -28 | N/A |
6/30/2022 | 24 | -36 | -76 | -30 | N/A |
3/31/2022 | 23 | -39 | -76 | -35 | N/A |
12/31/2021 | 22 | -43 | -76 | -39 | N/A |
9/30/2021 | 23 | -38 | -71 | -36 | N/A |
6/30/2021 | 25 | -34 | -66 | -32 | N/A |
3/31/2021 | 23 | -28 | -51 | -27 | N/A |
12/31/2020 | 21 | -23 | -35 | -22 | N/A |
12/31/2019 | 30 | -4 | N/A | N/A | N/A |
12/31/2018 | 25 | -2 | N/A | N/A | N/A |
12/31/2017 | 18 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABS's revenue (40% per year) is forecast to grow faster than the Norwegian market (1.8% per year).
High Growth Revenue: ABS's revenue (40% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABS is forecast to be unprofitable in 3 years.